NASDAQ: CALTCalliditas Therapeutics Ab Stock
$39.99+1.52 (+3.95%)
Updated May 31, 2024
CALT Price
$39.99
Fair Value Price
N/A
Market Cap
$1.19B
52 Week Low
$15.25
52 Week High
$40.00
P/E
-25.04x
P/B
38.71x
P/S
6.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$110.93M
Earnings
-$46.25M
Gross Margin
95%
Operating Margin
-28.39%
Profit Margin
-38.6%
Debt to Equity
4.55
Operating Cash Flow
-$43M
Beta
1.02
Next Earnings
Jun 17, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CALT Overview
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CALT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CALT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CALT is poor value based on its book value relative to its share price (38.71x), compared to the US Biotechnology industry average (6.04x)
P/B vs Industry Valuation
CALT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CALT due diligence checks available for Premium users.
Be the first to know about important CALT news, forecast changes, insider trades & much more!
CALT News
Valuation
CALT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-25.04x
Industry
-14.17x
Market
28.44x
CALT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
38.71x
Industry
6.04x
CALT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CALT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CALT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CALT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$184.4M
Liabilities
$151.2M
Debt to equity
4.55
CALT's short-term assets ($117.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CALT's short-term assets ($117.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CALT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CALT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CALT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CALT vs Biotech Stocks
Calliditas Therapeutics Ab Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.